Related Experiment Video
Updated: Aug 23, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
HIGH-DOSE INSULIN EUGLYCEMIC THERAPY
Jasmin Hamzić1, Dora Raos1, Bojana Radulović1
1Emergency Department, University Hospital Center Zagreb, Croatia.
Acta Clinica Croatica
|October 28, 2022
Summary
Calcium channel blocker and beta-blocker poisoning is a life-threatening emergency. High-dose insulin euglycemic therapy is a crucial treatment for these cardiac drug overdoses, improving patient outcomes.
Area of Science:
- Cardiology
- Toxicology
- Emergency Medicine
Background:
- Calcium channel blockers (CCBs) and beta-blockers (BBs) are common medications with significant toxicity risks.
- CCB and BB poisoning presents a frequent and potentially fatal challenge for emergency physicians.
- The characteristic toxidrome includes hypotension, bradycardia, arrhythmias, seizures, and temperature dysregulation.
Purpose of the Study:
- To review the mechanism of high-dose insulin euglycemic therapy (HIET) for CCB and BB toxicity.
- To propose a protocol for the application of HIET in poisoning cases.
- To address potential adverse effects associated with HIET.
Main Methods:
- Review of existing literature on CCB and BB poisoning.
- Analysis of the physiological effects of HIET.
- Development of a treatment protocol based on current evidence.
Main Results:
- HIET effectively counteracts the cardiotoxic effects of CCBs and BBs.
- Standard treatments like crystalloids, calcium, glucagon, and vasopressors may be insufficient alone.
- HIET offers a promising therapeutic strategy with manageable adverse effects.
Conclusions:
- HIET should be considered an integral component of managing CCB and BB poisoning.
- A structured protocol for HIET application is essential for emergency physicians.
- Further research may refine HIET protocols and expand its application in toxicology.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
227
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
227
01:15Hypoglycemia and Glucagon
311
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
311
01:15Diabetes: Management and Pharmacotherapy
331
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
331
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
266
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
266
01:06Oral Hypoglycemic Agents: Glinides
225
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
225
01:24Glucagon-like Receptor Agonists
386
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
386